{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigo442dawxdkoinqmfjkgggw6frevydxwmcs6ttzijrrl5gbvjmra",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mkuszlkngpc2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihwcw6msugolku4q65d6xfbsp25q74odcubrzajail63a6tyoxmby"
    },
    "mimeType": "image/jpeg",
    "size": 279256
  },
  "path": "/news/2026-04-experimental-kras-g12d-drug-cancer.html",
  "publishedAt": "2026-05-02T10:00:03.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of Medicine found that setidegrasib, an investigational targeted therapy drug designed to eliminate a key cancer-driving protein called KRAS G12D, shows encouraging early activity in patients with advanced lung and pancreatic cancers.",
  "title": "Experimental KRAS G12D drug slows cancer growth, shrinks tumors in early test"
}